Innovent Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug ListInnovent's SINTBILO® is officially included in the 2024 NRDL, marking a significant advancement in cholesterol management in China.
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)Innovent Biologics appoints Dr. Samuel Zhang as Global Chief Business Officer to oversee global strategy and business development.